Damelium® (Tablets) Instructions for Use
Marketing Authorization Holder
Actavis Group hf. (Iceland)
Manufactured By
Fal Duiven, B.V. (Netherlands)
ATC Code
A03FA03 (Domperidone)
Active Substance
Domperidone (Rec.INN registered by WHO)
Dosage Form
| Damelium® | Tablets 10 mg: 10 or 30 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, round, biconvex, with an engraving “Dm10” on one side.
| 1 tab. | |
| Domperidone maleate | 12.72 mg, |
| Equivalent to domperidone content | 10 mg |
Excipients: lactose monohydrate, corn starch, magnesium stearate, colloidal silicon dioxide, microcrystalline cellulose, povidone, sodium lauryl sulfate.
10 pcs. – blisters (1) – packs.
10 pcs. – blisters (3) – packs.
Clinical-Pharmacological Group
Centrally acting antiemetic drug blocking dopamine receptors
Pharmacotherapeutic Group
Antiemetic agent – central dopamine receptor antagonist
Pharmacological Action
Antiemetic agent. It has an antiemetic effect, soothes hiccups and in some cases eliminates nausea. The action is due to the blockade of central dopamine receptors. This eliminates the inhibitory effect of dopamine on the motor function of the gastrointestinal tract and increases the evacuation and motor activity of the stomach.
Pharmacokinetics
Absorption after oral administration on an empty stomach is rapid (administration after meals, reduced gastric acidity slow down and reduce absorption). Cmax is reached in 1 h. Bioavailability is 15% (effect of “first pass” through the liver). Plasma protein binding is 90%. It penetrates into various tissues, poorly passes through the blood-brain barrier. It is metabolized in the liver and in the intestinal wall (by hydroxylation and N-dealkylation). It is excreted through the intestine 66%, by the kidneys – 33%, including unchanged – 10% and 1%, respectively. T1/2 is 7-9 h, in severe chronic renal failure it is prolonged.
Indications
Nausea, vomiting, hiccups of various origins (in toxemia, radiation therapy, dietary disorders, intake of certain drugs /morphine/, endoscopic and radiopaque studies, in the postoperative period). Postoperative hypotension and atony of the stomach and intestines, biliary dyskinesia, flatulence, reflux esophagitis, cholecystitis, cholangitis, various types of dyspepsia. Nausea and vomiting caused by the intake of dopamine mimetics.
ICD codes
| ICD-10 code | Indication |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K30 | Functional dyspepsia (digestive disorder) |
| K31.8 | Other specified diseases of stomach and duodenum |
| K59.8 | Other specified functional intestinal disorders |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K82.8 | Other specified diseases of gallbladder and cystic duct (including dyskinesia) |
| K83.0 | Cholangitis |
| R06.6 | Hiccough |
| R11 | Nausea and vomiting |
| R14 | Flatulence and related conditions (including abdominal bloating, belching) |
| ICD-11 code | Indication |
| DA22.Z | Gastro-esophageal reflux disease, unspecified |
| DA24.Z | Unspecified esophagitis |
| DA40.2 | Volvulus of stomach |
| DA41.0Z | Unspecified disorder of stomach motility |
| DA41.2 | Acid hyper secretion |
| DA41.3 | Achlorhydria |
| DA43.1 | Angiodysplasia of stomach |
| DA43.2 | Arteriovenous malformation of the stomach |
| DA43.3 | Gastropathy in portal hypertension |
| DA43.4 | Diffuse gastric vascular ectasia |
| DA4Y | Other specified diseases of the stomach |
| DA50.3 | Deformation of duodenum, acquired |
| DA52.1 | Angiodysplasia of duodenum |
| DA52.2 | Arteriovenous malformation of duodenum |
| DA52.Y | Other specified vascular diseases of duodenum |
| DA7Z | Diseases of stomach or duodenum, unspecified |
| DB32.3 | Acquired hypoganglionosis of the colon |
| DB32.Z | Colonic motility disorders, unspecified |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC13 | Cholangitis |
| DC1Z | Diseases of gallbladder and biliary tract, unspecified |
| DD90.0 | Globus sensation |
| DD90.1 | Functional dysphagia |
| DD90.2 | Functional heartburn |
| DD90.3 | Functional dyspepsia |
| DD90.Z | Functional disorders of esophagus or gastroduodenal system, unspecified |
| DD91.Y | Other specified irritable bowel syndrome or functional bowel disorders |
| DD93.Y | Other specified functional gastrointestinal disorders in infants, toddlers and school-age children |
| DD94 | Functional disorder of the gallbladder |
| MD11.6 | Hiccough |
| MD90 | Nausea or vomiting |
| ME08 | Flatulence and related conditions |
| ME24.3Y | Other specified perforation in the area of the gastrointestinal tract |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally.
Take tablets 15-30 minutes before meals.
For adults and adolescents 12 years and older (with body weight of 35 kg or more), the usual dose is one 10 mg tablet three to four times daily.
Do not exceed the maximum daily dose of 30 mg (3 tablets).
The duration of treatment should not exceed one week for nausea and vomiting.
For chronic conditions like dyspepsia, treatment duration may be extended as determined by a physician.
In patients with severe renal impairment (serum creatinine >6 mg/100 ml), reduce the dosing frequency to once or twice daily.
In patients with hepatic impairment, use with caution and consider a reduced dosage.
The tablet may be placed on the tongue and swallowed with water.
Adverse Reactions
From the central nervous system rarely – increased excitability and/or extrapyramidal disorders, headache.
From the digestive system spasms of the smooth muscles of the gastrointestinal tract, dry mouth, thirst.
Allergic reactions itching, rash, urticaria.
Other increased plasma prolactin levels, galactorrhea, gynecomastia.
Contraindications
Gastrointestinal bleeding, mechanical intestinal obstruction, perforation of the stomach or intestine, prolactinoma, pregnancy, lactation (breastfeeding), hypersensitivity to domperidone; children under 12 years of age and body weight less than 35 kg (for tablets).
Use in Pregnancy and Lactation
Domperidone is contraindicated for use during pregnancy and lactation.
Use in Hepatic Impairment
It should be used with caution in case of liver function disorders.
Use in Renal Impairment
It should be used with caution in case of renal function disorders. In renal failure, the frequency of administration should be reduced.
Pediatric Use
Contraindicated in children under 1 year of age (under 5 years of age and children with body weight less than 20 kg – for tablets).
Special Precautions
It should be used with caution in case of liver and kidney function disorders.
Drugs containing Domperidone should be administered to children in dosage forms intended for the appropriate age.
Drug Interactions
With simultaneous use with antacids, antisecretory drugs (including cimetidine, sodium bicarbonate), the bioavailability of domperidone decreases.
With simultaneous use with anticholinergic drugs, the effect of domperidone is suppressed.
Since Domperidone is metabolized mainly with the participation of the CYP3A4 isoenzyme, it is believed that with simultaneous use of domperidone and inhibitors of this isoenzyme (including azole antifungal drugs, macrolide antibiotics, HIV protease inhibitors, nefazodone), an increase in the plasma level of domperidone is possible.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer